share_log

PURE Bioscience (OTCMKTS:PURE) Share Price Passes Above Two Hundred Day Moving Average of $0.19

Defense World ·  Sep 3, 2022 02:11

PURE Bioscience, Inc. (OTCMKTS:PURE – Get Rating)'s stock price passed above its 200-day moving average during trading on Friday . The stock has a 200-day moving average of $0.19 and traded as high as $0.23. PURE Bioscience shares last traded at $0.23, with a volume of 114,685 shares.

PURE Bioscience Price Performance

The firm has a market capitalization of $20.24 million, a price-to-earnings ratio of -5.75 and a beta of 0.02. The business's fifty day simple moving average is $0.20 and its 200 day simple moving average is $0.19.

Get PURE Bioscience alerts:

PURE Bioscience (OTCMKTS:PURE – Get Rating) last issued its quarterly earnings data on Tuesday, June 14th. The company reported ($0.01) earnings per share (EPS) for the quarter. The business had revenue of $0.50 million for the quarter. PURE Bioscience had a negative net margin of 131.59% and a negative return on equity of 131.39%.

About PURE Bioscience

(Get Rating)

PURE Bioscience, Inc develops and commercializes antimicrobial products that provide solutions to the health and environmental challenges of pathogen and hygienic control in the United States and internationally. The company manufactures and distributes silver dihydrogen citrate (SDC), a non-toxic antimicrobial agent, which offers residual protection, as well as formulates with other compounds.

Recommended Stories

  • Get a free copy of the StockNews.com research report on PURE Bioscience (PURE)
  • Could Snap Stock Rebound As Management Restructures?
  • MarketBeat: Week in Review 8/29 – 9/2
  • Hormel Looks Cheap At These Levels
  • Lululemon Set To Soar Into September
  • Could Nike Stock be Oversold, but Still Overvalued?

Receive News & Ratings for PURE Bioscience Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for PURE Bioscience and related companies with MarketBeat.com's FREE daily email newsletter.

Disclaimer: This content is for informational and educational purposes only and does not constitute a recommendation or endorsement of any specific investment or investment strategy. Read more
    Write a comment